InvestSMART

Nova Eye Medical Limited (ASX:EYE)

ALERT: Price-sensitive ASX Announcement for EYE
Current share price for EYE : $0.140 0.02 (16.67%)+
Announcement
Release
29 Jul 2026 11:03AM
Price at Release
$0.120
Full Release
download
Summary
Nova Eye Medical Limited reported a strong performance for the year ending 30 June 2026, achieving a revenue of US$23.7 million, marking the fourth consecutive year of sales growth above 25%. The company's sales growth was driven by markets excluding China, with the United States showing a significant increase of 30%. The company also reported its first half of positive EBITDA, achieving US$0.14 million in the second half of FY26. Nova Eye Medical's liquidity is stable with A$3.7 million in cash and unused debt facilities. Guidance for FY27 expects sales, excluding China, to be between US$26 million and US$31 million, with a focus on maintaining a positive EBITDA. The company is well-positioned in the global interventional glaucoma market, which is valued at approximately US$944 million, and continues to invest in market activation and education initiatives to support growth.
Key Points
  • Total sales for the year ended 30 June 2026 were US$23.7 million.
  • Sales growth has exceeded 25% for four consecutive years.
  • Sales in the USA increased by 30% year-over-year.
  • The company reported a positive EBITDA of US$0.14 million in H2FY26.
  • Cash and liquidity position is stable with A$3.7 million available.
  • Guidance for FY27 anticipates US$26-31 million in sales excluding China.
  • The global interventional glaucoma market is valued at US$944 million.
  • Nova Eye Medical focuses on market activation and surgeon training.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.